Category

Archives

Androgen Receptor

Impact of New Systemic Therapies in Overall Survival in Non-Metastatic Castration Resistant Prostate Cancer: Systematic Review and Meta-Analysis

32 views | Dec 20 2021

Alejo Rodriguez-Vida et al. found that first-line treatment of nmCRPC patients with anti-androgens increased OS with an acceptable safety profile. [Read the Full Post]

Prostate Cancer Detected by Choroidal Tumor and Complete Response to Hormonal Therapy: Case Report and Literature Review of 24 Patients With Choroidal Metastasis From Prostate Cancer

148 views | Jun 25 2021

Toshihiko Matsuo et al. found that metastatic choroidal tumors of prostate cancer would show good response to hormonal therapy when the therapy had not been initiated. [Read the Full Post]

Prognostic value of [ 18 F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies

166 views | May 14 2021

Simone Krebs et al. found that higher lesional metabolic parameters were inversely related to outcome in patients undergoing ibrutinib-based therapies, and sumSUVmax emerged as a strong independent prognostic factor. [Read the Full Post]

Physcion, a novel inhibitor of 5α-reductase that promotes hair growth in vitro and in vivo

141 views | Mar 02 2021

Zizhao Lao et al. suggested that Physcion was a potent 5α-reductase inhibitor, as well as a new natural medicine for treating AGA. [Read the Full Post]

Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary

154 views | Dec 30 2020

Martin R Hofmann wt al. proposed that there was no high level clinical evidence for treatment selection among these choices based on biological drivers of clinical disease. [Read the Full Post]

Low-Dose Enzalutamide in Late-Elderly Patients (≥ 75 Years Old) Presenting With Metastatic Castration-Resistant Prostate Cancer.

227 views | May 19 2020

Vinh-Hung V et al. found that Low-dose enzalutamide in very old, symptomatic, poor-performance patients with metastatic disease was associated with high response rate and survival comparable to standard dose. [Read the Full Post]

Inhibition of the erythropoietin-producing receptor EPHB4 antagonizes androgen receptor overexpression and reduces enzalutamide resistance

0 views | May 13 2020

Li C et al. provided critical insight into the mechanism of enzalutamide resistance in PCa, potentially offering a therapeutic avenue for enhancing the efficacy of enzalutamide to better manage this common malignancy. [Read the Full Post]

Investigation of lncRNA H19 in prostate cancer cells and secreted exosomes upon androgen stimulation or androgen receptor blockage

244 views | May 06 2020

Ozgur E et al. provided evidence that H19 might be involved in androgen receptor pathway. [Read the Full Post]

Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer With and Without Prior Abiraterone Acetate and Prednisone

223 views | Apr 23 2020

Dana E Rathkopf et al. indicated that apalutamide was safe, well tolerated, and demonstrated clinical activity in mCRPC, with 80% of AAP-naïve and 43% of post-AAP patients, remaining on treatment for 6 months or longer. [Read the Full Post]

Inhibition of the erythropoietin-producing receptor EPHB4 antagonizes androgen receptor overexpression and reduces enzalutamide resistance

232 views | Mar 20 2020

Li C et al. provided critical insight into the mechanism of enzalutamide resistance in PCa, potentially offering a therapeutic avenue for enhancing the efficacy of enzalutamide to better manage this common malignancy. [Read the Full Post]